Arshad M. Khanani, MD
Show Description +
Arshad M. Khanani, MD, explains the results from the Phase 3a MERLIN trial of brolucizumab in patients with wet AMD; the therapy had superior drying effects, but an increased rate of adverse events.
Posted: 11/17/2021
Arshad M. Khanani, MD
Arshad M. Khanani, MD, explains the results from the Phase 3a MERLIN trial of brolucizumab in patients with wet AMD; the therapy had superior drying effects, but an increased rate of adverse events.
Posted: 11/17/2021
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2021.
Please log in to leave a comment.